Bernard Silverman, MD
Allergy & Immunology · Brooklyn, NYNPI 1033192836
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,403 of the $62,996 with a category attached, or 92.7%. Janssen Research & Development, LLC accounts for 92.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $59,371, more than ten times the $2,573 reported in 2019. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $670.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$58K
- Astrazeneca UK Limited$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$290
- GSK$284
- AstraZeneca$222
- plus $740 from 9 others
Across 21 payments — averaging $5278.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$59K
- Astrazeneca UK Limited$38K
- AstraZeneca$10K
- Novartis$5K
What the payments were for
- Consulting fees$58,40393%
- Travel & lodging$1,2522%
- Food & beverage$3,3415%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 4 | $58,403 |
| Astrazeneca UK Limited | 8 | $1,930 |
| Sanofi | 22 | $1,127 |
| Regeneron Healthcare Solutions, Inc. | 7 | $290 |
| GSK | 17 | $284 |
| AstraZeneca | 9 | $222 |
| Genentech USA, Inc. | 8 | $163 |
| Amgen | 4 | $157 |
| Novartis | 6 | $139 |
| Alk-abello, Inc | 1 | $111 |
| Merck | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| CSL Behring | 1 | $31 |
| Kaleo, Inc. | 1 | $24 |
| Circassia Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,996 in reported general payments places this provider in the 90th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 134 | $1,577 |
| Montelukast Sodium | 23 | $50 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Brooklyn
- Payel GuptaBrooklyn$256K
- Dina LibermanBrooklyn$34K
- Richard KolchinBrooklyn$20K
- David SanchezBrooklyn$13K
- Jenny ShliozbergBrooklyn$12K
- Ujwala KazaNew York$1.1M
- Syed MustafaRochester$948K
- Robert SporterNew York$946K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$643K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.